Japanese patent for our Therapy
Therapy: Publication of the Japan patent grant. On March 22, 2017, the Japanese Patent Office granted the patent for our therapy with No. 6100276 “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy”. Japan Patent No. JP6100276B2…
Therapy: Publication of the Japan patent grant.
On March 22, 2017, the Japanese Patent Office granted the patent for our therapy with No. 6100276 “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy”.